Type 2 Diabetes Mellitus hypoglycaemic agents

Similar documents
Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

Navigating the New Options for the Management of Type 2 Diabetes

Treatment Options for Diabetes: An Update

Oral and Injectable Non-insulin Antihyperglycemic Agents

How can we improve outcomes in Type 2 diabetes?

Glucose Control drug treatments

Dept of Diabetes Main Desk

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Pharmacologic Agents for Treatment of Type 2 Diabetes

Non-Insulin Diabetes Medications Summary

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?

Very Practical Tips for Managing Type 2 Diabetes

Newer Drugs in the Management of Type 2 Diabetes Mellitus

What s New in Diabetes Medications. Jena Torpin, PharmD

Table 1. Antihyperglycemic agents for use in type 2 diabetes

New Antidiabetic Medications

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Diabetes Medications: Oral Anti-Hyperglycemic Medications

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

The Death of Sulfonylureas? A Review of New Diabetes Medications

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

What s New in Diabetes Treatment. Disclosures

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

DM Fundamentals Class 4 Meds for Type 2

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

PLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

I. General Considerations

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

Overview T2DM medications. Winnie Ho

DM Fundamentals Class 4 Meds for Type 2

MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?

MANAGEMENT OF TYPE 2 DIABETES

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

Current and future market dynamics overview

Oral Treatments for Type 2 Diabetes. Prescribing Support Pharmacist

February 2016 DIABETES PHARMACY TEAMS MAKE A DIFFERENCE. Why am I here? Why are you here? Identifying people at risk. What can we do?

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Drug Class Review Newer Diabetes Medications and Combinations

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

STEP 3: Add or Substitute with one of

Wayne Gravois, MD August 6, 2017

Management of Type 2 Diabetes

TYP 2 DIABETES. Marc Donath

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care

Oral Treatments. SaminaAli Prescribing Support Pharmacist

Diabetes Mellitus II CPG

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

New Therapies for Diabetes

Mr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)

Pharmacological Glycaemic Control in Type 2 Diabetes

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

3. Cardiovascular Disease?

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

Management of Diabetes

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test

Management of Diabetes Mellitus: A Primary Care Perspective

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

How they work and when to take them. Diabetes Medications

Diabetes 2016: Strategies for achieving optimal diabetes control

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

Update Diabetes Therapie. Marc Y Donath

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

Dr A Pokrajac MD MSc MRCP Consultant

MANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC

Arrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol

Rebecca Newberry APRN MS CDE

Drug Class Monograph

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes

Drug Class Monograph

Early treatment for patients with Type 2 Diabetes

Date of Review: September 2016 Date of Last Review: September 2015

CURRENT ISSUES IN DIABETES MANAGEMENT

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Alia Gilani Health Inequalities Pharmacist

Drugs used in Diabetes. Dr Andrew Smith

Inpatient Diabetes 20/01/2015. What should I do? Hyperglycaemia why does it matter? Why are the BSLs unstable? BSL parameters

Advanced Practice Education Associates. Endocrine

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION

Diabetes Treatment Guidelines

DIABETES DEBATE - IS NEW BETTER?

SGLT2 Inhibitors

Management of Type 2 Diabetes: Should We Change Our Algorithm?

PRINCIPLES OF ORAL ANTIDIABETIC AND

Diabetes management in liver and kidney disease

Transcription:

Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic acidosis - (so not if liver disease, renal impairment, alcohol issues, and careful if >80yo.) B12 defn in long term use and increased homocysteine levels (5) "Claimed" Hba1c benefit vs placebo (time maintained)* ~1% (10mts- 1.5g) Side effects Diarrhoea Nausea Bloating (20-30% but 5% have to cease) Keys to remember! First line Decreased all cause mortality and BETTER CV profile. Reduces LDL MUST Stop if egfr <30 or Lactic Acidosis possible! Sulfonylurea Gliclazide (Diamicron), Glipizide, Glipenclamide, (Glimel) Glimepiride (diapride) $15.77 (1 dly)?increased all cause mortality?increased CV disease risk?stroke Studies ongoing. (4) ~1.25% (2yrs) Weight gain Hypoglycaemia Can cause Hypoglycaemia Possible all cause mortality issues? Weight gain possible! Thiazolidinediones Pioglitiazone (Actos) Rosiglitazone (Avandia) $75 (1 dly) Pioglitazone - Small increase in bladder cancer Rosiglitazone - increased CV events & worse cholesterol profile ~1-1.5% (0.5yrs) Muscle pain Dizziness Headaches Arthralgias Iron deficiency Be wary in heart failure, elevated cholesterol, and macular family history issues. Expensive. Fluid retention - Not for NYHF 3/4 Macular oedema?osteoporosis Mild increase in weight? (1)

DPP4 - Inhibitors SGLT2 inhibitors Sitagliptin (Januvia) Saxagliptin (Onglyza) Dapagliflozin (Forxiga) Canagliflozin (Invokana) $75 (1 dly) Onglyza -?increased bone fractures Pancreatitis possible in the other types $75 (1 dly) Genital infections in 8% (usually thrush - M&F) UTI also more common?? Bone effects ~0.75% (1 yr) No weight gain Dizziness Headaches Cold-like symptoms Increased infections Resp/Urinary ~1% (0.5yrs) ~ 0.5% (1yr) Polyuria, frequency, nocturia thirst Weight reduction 2-3kg (at 24wks - uncertain longer) (7)? Reduction in BP? Expensive. Watch for abdominal pain for pancreatitis Possible benefit of CV profile? Ongoing research. Early days for this medication.?genital infections and UTI risks Maybe not for post menopausal women? GLP1-agonists (Injectable only) Acarbose Exenatide (Byetta) $36.90 (1-60U of 5 or 10mcg doses) Acarbose (Glucobay) $36.90 (1dly) Pancreatitis Not for egfr <30 (3) Hepatitis Cannot use in IBD or bowel obstructions (partial) Ileus Anaemia Oedema ~ -1.5% (2) Nausea, vomiting, weight loss, heartburn, dizziness, headache ~1% v Placebo ( 2yrs) Flatulence Diarrhoea Hypoglycaemia Watch for abdominal pain for pancreatitis. (Maybe don't start if risk factors for this.) Not for egfr <30 Very difficult to tolerate

Side effects at a glance table Name Increased CVR Weight Change Hypo Risk LDL Change (8) GI side effects! Genital infection and?maybe UTI Metformin " " - significant Sulfonylurea!?! - mild Glitazones!?! Min DPP4-Inhib "? (10) Min SGLT2 inhib? "? 2-3 kg (24wks) GLP-1 agonist "? " - Mild (?6%) (9) Acarbose " (13) (12) Reduced (11)! - SIGNIF

References: Primary Reference: Systematic review and Meta-analysis on type 2 DM medications. Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J. E., & Gerstein, H. C. (2010). The Effect of Oral Antidiabetic Agents on A1C Levels A systematic review and meta-analysis. Diabetes Care, 33(8), 1859-1864. Metformin reference: http://bjcardio.co.uk/2010/09/drugs-for-diabetes-part-1-metformin/ Sulfonylurea Reference: http://www.ncbi.nlm.nih.gov/pubmed/23594109 http://www.medscape.com/viewarticle/811641#2 (Though careful as researcher sponsored by AstraZeneca, Novo-Nordisk, and Bristol-Myers Squibb) Glitazones reference: http://www.nps.org.au/conditions/hormones-metabolism-and-nutritional-problems/diabetes-type-2/for-individuals/medicines-and-treatments/glitazones http://www.ncbi.nlm.nih.gov/pubmed/11092281 SGLT2 reference: http://www.racgp.org.au/afp/2013/october/sglt2-inhibition-with-dapagliflozin/ DPP4 - Gliptins Reference: http://www.nps.org.au/conditions/hormones-metabolism-and-nutritional-problems/diabetes-type-2/for-individuals/medicines-and-treatments/gliptins (1) - http://www.who.int/selection_medicines/committees/expert/19/applications/oralhypoglycemics_18_5_a_r.pdf (2) - http://www.medscape.com/viewarticle/724233 (3) - http://www.mhra.gov.uk/safetyinformation/drugsafetyupdate/con088117 (4) - http://www.medscape.com/viewarticle/811641 & http://dvr.sagepub.com/content/early/2013/01/03/1479164112465442.full (5) - http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2796.2003.01213.x/full (7) - http://bjcardio.co.uk/2012/03/drugs-for-diabetes-part-8-sglt2-inhibitors/ (8) - https://secure.sherbornegibbs.com/bjdvd/pdf/1008.pdf (9) - http://www.diabetesincontrol.com/articles/54-/12066-successful-weight-loss-with-glp-1-agonists (10) - http://www.ncbi.nlm.nih.gov/pubmed/23748503 (11) - http://www.ncbi.nlm.nih.gov/pubmed/11242714 (12) - http://www.ncbi.nlm.nih.gov/pubmed/9376887 (13) - http://bjcardio.co.uk/2011/04/drugs-for-diabetes-part-4-acarbose/

Mode of Action Physiology Refresher Metformin: Decreases gluconeogenesis of the liver Increases glucose uptake at muscle. Increases insulin sensitivity in the liver Sulfonylurea: Causes an increased release of insulin from the pancreas Glitazones: Increases insulin sensitivity SGLT-2 inhibitors: These BLOCK reuptake of glucose by the nephron and therefore you urinate out the extra glucose Acarbose: Inhibits enzymes required to digest carbohydrates DPP4 Inhibitors: (Remember this is ONE STEP BEFORE GLP1 agonists - Byetta - so remember them together!) Glucagon increases blood glucose --> DPP4 inhibitors increase incretin. Incretin BLOCKS glucagon release and increases insulin release. This DECREASES blood glucose. Avandamet = Rosiglitazone + Metformin Galvumet = Vildagliptin + Metformin Glucovance = Glibenclamide + Metformin Janumet XR = Sitagliptin + Metformin Kombiglyze XR = Saxagliptin + Metformin Nesina Met = Alogliptin + Metformin Trajentamet = Linagliptin + Metformin Combinations

PBS Restrictions brief summary SUMMMARY of PBS restrictions for second line medications (other than sulfonylureas) (see full details on PBS website - Link). You need all 3 of these... 1. Must be used either with metformin OR Sulfonylurea 2. Must have a contraindication to combination of Meformin and Sulfonylurea or have not tolerated them 3. Must have HbA1c measurement >7%, within the last 4mths, PRIOR to intiation despite treatment with metformin or sulfonylurea and you must write this in the notes